Keyphrases
Chemotherapy
100%
Lung Cancer Patients
100%
Multicenter Retrospective Cohort Study
100%
Maintenance Hemodialysis Patients
100%
Real-world Outcomes
100%
Hemodialysis Patients
42%
Objective Response Rate
28%
Median Overall Survival
28%
Non-small Cell Lung Cancer Cells
28%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
28%
Lung Cancer
28%
Treatment-related Mortality
28%
EGFR mutation
28%
Non-small Cell Lung Cancer Patients
28%
Cytotoxic Chemotherapy
28%
Japan
14%
Patient Characteristics
14%
In(III)
14%
Multicenter Retrospective Study
14%
Chemoradiotherapy
14%
Survival Benefit
14%
Real-world Clinical Practice
14%
Cause of Death
14%
Non-small Cell Lung Cancer (NSCLC)
14%
Best Supportive Care
14%
Treatment-related Adverse Events
14%
Clinical Information
14%
Febrile Neutropenia
14%
Cancer Stage
14%
Malignant Tumor
14%
End-stage Renal Disease
14%
Small Cell Lung Cancer
14%
Myelosuppression
14%
EGFR Wild-type
14%
Lack of Information
14%
Palliative Chemotherapy
14%
Renal Safety
14%
Medicine and Dentistry
Retrospective Cohort Study
100%
Lung Cancer
100%
Hemodialysis
100%
Chemotherapy
100%
Epidermal Growth Factor Receptor
62%
Non Small Cell Lung Cancer
50%
Tyrosine-Kinase Inhibitor
25%
Overall Survival
25%
Small Cell Lung Cancer
25%
Cytotoxic Chemotherapy
25%
Patient Characteristics
12%
Cancer Staging
12%
Retrospective Study
12%
Adverse Event
12%
Chemoradiotherapy
12%
Malignant Neoplasm
12%
Supportive Care
12%
Febrile Neutropenia
12%
End Stage Renal Disease
12%
Bone Marrow Suppression
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Lung Cancer
100%
Cohort Study
100%
Hemodialysis
100%
Epidermal Growth Factor Receptor
62%
Non Small Cell Lung Cancer
50%
Overall Survival
25%
Protein Tyrosine Kinase Inhibitor
25%
Small Cell Lung Cancer
25%
Cytotoxic Chemotherapy
25%
Malignant Neoplasm
12%
Cancer Staging
12%
Adverse Event
12%
Retrospective Study
12%
Chemoradiation Therapy
12%
Febrile Neutropenia
12%
End Stage Renal Disease
12%
Bone Marrow Suppression
12%